**Abstract**

There is an urgent need for biomarkers of bipolar disorder to optimize its treatment. Although inflammatory markers have been most established biomarkers of bipolar disorder, molecular basis of cytokine elevation is not known. We hypothesized that plasma mitochondrial DNA (mtDNA), one of mitochondrial damage-associated molecular patterns, would contribute to inflammation observed in bipolar disorder. The purpose of the present study was to evaluate whether plasma mtDNA is useful as a biomarker. We measured plasma mtDNA level (copy number) in two sets of samples. In the first set, (11 medicated patients with bipolar disorder and 10 healthy controls), plasma mtDNA was measured by quantitative PCR and plasma IL-6, TNF-α, and CRP were measured by ELISA. In the second set, subjects with no medication; six bipolar disorder, 19 healthy controls, five major depressive disorder, and 16 schizophrenia, plasma mtDNA was measured. This study was approved by the ethics committees of Hannan Hospital, Osaka City University, RIKEN, and National Center of Neurology and Psychiatry and conducted in accordance with the Declaration of Helsinki. In the first set, there was no significant difference in plasma mtDNA level between patients with bipolar disorder and healthy controls. IL-6 showed a non-significant tendency of higher level in patients with bipolar disorder compared with controls (*p* = 0.06) and there was a trend of positive correlation between plasma mtDNA level and IL-6 level (*r* = 0.45). There was no significant differences in mtDNA level in the second set as well. In summary, these findings did not support our hypothesis that plasma mtDNA would be a biomarker of bipolar disorder. To draw a conclusion, however, further studies in cerebrospinal fluid would be needed. The positive correlation between mtDNA level and IL-6 level warrants investigation in larger samples.
